Vascular Closure Devices Global Market – Forecast To 2022
Vascular closure is a procedure done for the closure of the punctured arterial wall after the performance of the catheterization procedure using the active and passive approximators. The active and passive approximators are the vascular closure device that reduce the blood loss with better haemostasis and reduce the time of ambulation with an increase the patient comfort. They are designed to provide quick and reliable haemostasis of access site after the invasive catheterization procedure. They were introduced in the 1990’s to overcome the complications caused by the manual compression. The vascular closure global market is valued at $XX million in 2015 and expected to grow at a high single digit CAGR to reach $1,665.2 million by 2022. The vascular closure devices global market is segmented by product type, access, intervention and geography.
Increasing catheterization related procedures (PCI), preference for minimally-invasive solutions & rise in vascular procedures, ease in usage and quick hemostatic properties of VCDs, and increased utilization of transradial arterial access are driving the growth of the market.
High price of products, complications associated with VCD, less adoption of novel technologies in emerging countries are hampering the market of vascular closure. Reduced reimbursement, usage of animal related sources and lower revenue potential of VCD are threats for the market growth.
The vascular closure device global market by products is segmented into active approximators and passive approximators. Active approximators are sub-segmented into clips, plugs and suture mediated device. Plugs are further divided into FISH, collagen based and polymer based plugs. Active approximators hold the largest share in 2015 and are growing at a CAGR of 7.5% and passive approximators is expected to grow at high single digit CAGR by 2022.
The vascular closure devices global market by intervention is mainly segmented into diagnostics and intervention. The diagnostic vascular closure devices global market hold the largest share in 2015 and expected to grow at a highest CAGR of 8.7% and therapeutic vascular closure devices segment is expected to grow at a CAGR of XX% by 2022.
The vascular closure global market by access is mainly segmented into femoral access and radial access. The femoral vascular closure devices global market hold the largest share in 2015 and expected to reach $XX million in 2022, at a CAGR of XX% and radial vascular access segment is also expected to grow at a highest CAGR to reach $340.9 by 2022.
The vascular closure devices global market by geography is divided into North America, Europe, Asia-Pacific and Rest of the world. North American region commanded the largest market share in 2015 and expected to reach $XX million by 2022, at high single digit CAGR due to increasing catheterization related procedures (PCI), preference for minimally-invasive solutions & rise in vascular procedures, ease in usage and quick hemostatic properties of VCDs and increased utilization of transradial arterial access. Europe region is expected to grow at a CAGR of XX% from 2015 to 2022 following the North American region.
Major players in the vascular closure market are Abbott Laboratories (U.S.), Advanced Vascular Dynamics (U.S.), B Braun Melsungen AG (Germany), Biotronik International (Germany), C R Bard (U.S.), Cardinal Health (U.S.), Cardiva Medical (U.S.), Morris Innovative (U.S.), Scion Biomedical (U.S.), St Jude Medical (U.S.), Terumo (Japan) and Vascular Solutions (U.S.).
Increasing catheterization related procedures (PCI), preference for minimally-invasive solutions & rise in vascular procedures, ease in usage and quick hemostatic properties of VCDs, and increased utilization of transradial arterial access are driving the growth of the market.
High price of products, complications associated with VCD, less adoption of novel technologies in emerging countries are hampering the market of vascular closure. Reduced reimbursement, usage of animal related sources and lower revenue potential of VCD are threats for the market growth.
The vascular closure device global market by products is segmented into active approximators and passive approximators. Active approximators are sub-segmented into clips, plugs and suture mediated device. Plugs are further divided into FISH, collagen based and polymer based plugs. Active approximators hold the largest share in 2015 and are growing at a CAGR of 7.5% and passive approximators is expected to grow at high single digit CAGR by 2022.
The vascular closure devices global market by intervention is mainly segmented into diagnostics and intervention. The diagnostic vascular closure devices global market hold the largest share in 2015 and expected to grow at a highest CAGR of 8.7% and therapeutic vascular closure devices segment is expected to grow at a CAGR of XX% by 2022.
The vascular closure global market by access is mainly segmented into femoral access and radial access. The femoral vascular closure devices global market hold the largest share in 2015 and expected to reach $XX million in 2022, at a CAGR of XX% and radial vascular access segment is also expected to grow at a highest CAGR to reach $340.9 by 2022.
The vascular closure devices global market by geography is divided into North America, Europe, Asia-Pacific and Rest of the world. North American region commanded the largest market share in 2015 and expected to reach $XX million by 2022, at high single digit CAGR due to increasing catheterization related procedures (PCI), preference for minimally-invasive solutions & rise in vascular procedures, ease in usage and quick hemostatic properties of VCDs and increased utilization of transradial arterial access. Europe region is expected to grow at a CAGR of XX% from 2015 to 2022 following the North American region.
Major players in the vascular closure market are Abbott Laboratories (U.S.), Advanced Vascular Dynamics (U.S.), B Braun Melsungen AG (Germany), Biotronik International (Germany), C R Bard (U.S.), Cardinal Health (U.S.), Cardiva Medical (U.S.), Morris Innovative (U.S.), Scion Biomedical (U.S.), St Jude Medical (U.S.), Terumo (Japan) and Vascular Solutions (U.S.).
1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing catheterization related procedures
3.3.1.2 Preference for minimally-invasive solutions
3.3.1.3 Ease in usage and quick hemostatic properties of VCDs
3.3.1.4 Increased utilization of transradial arterial access
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High price of products
3.3.2.2 Complications associated with VCD
3.3.2.3 Less adoption of novel technologies in emerging countries
3.3.2.4 Reduced reimbursement
3.3.2.5 Usage of animal related sources
3.3.2.6 Lower revenue potential of VCD
3.4 PORTER’S FIVE FORCE ANALYSIS
3.4.1 THREAT OF NEW ENTRANTS
3.4.2 THREAT OF SUBSTITUTES
3.4.3 BARGAINING POWER OF SUPPLIERS
3.4.4 BARGAINING POWER OF BUYERS
3.4.5 COMPETITIVE RIVALRY
3.5 REGULATORY AFFAIRS
3.5.1 U.S.
3.5.2 EUROPE
3.5.3 INDIA
3.5.4 CHINA
3.5.5 JAPAN
3.6 REIMBURSEMENT SCENARIO
3.6.1 TRANSCATHETER EMBOLIZATION OR OCCLUSION SERVICES
3.6.2 THROMBOLYSIS
3.6.3 DIAGNOSTIC CARDIAC CATHETERIZATION
3.6.4 INJECTION DIAGNOSTIC CARDIAC CATHETERIZATION
3.7 UPCOMING TECHNOLOGIES
3.8 SUPPLY CHAIN ANALYSIS
3.9 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.10 PATENT TRENDS
4 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY TYPE
4.1 INTRODUCTION
4.2 ACTIVE APPROXIMATORS
4.2.1 CLIPS
4.2.2 SUTURE MEDIATED DEVICES
4.2.3 PLUGS
4.2.3.1 Collagen based
4.2.3.2 Polymer based
4.2.3.3 FISH
4.3 PASSIVE APPROXIMATORS
4.3.1 HEMOSTATIC PADS/PATCHES
4.3.2 COMPRESSION DEVICES
5 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY INTERVENTION
5.1 INTRODUCTION
5.2 DIGNOSTICS
5.3 THERAPEUTICS
6 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY ACCESS
6.1 INTRODUCTION
6.2 FEMORAL ACCESS
6.3 RADIAL ACCESS
7 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY GEOGRAPHY
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.3 EUROPE
7.4 ASIA PACIFIC
7.5 REST OF THE WORLD
8 COMPANY DEVELOPMENTS
8.1 INTRODUCTION
8.2 ACQUISITION AS A MAJOR GROWTH STRATEGY OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYERS
8.3 MERGERS AND ACQUISITION
8.4 AGREEMENTS PARTERNER SHIPS, COLLABORATIONS & JOINT VENTURES
8.5 APPROVALS
8.6 BUSINESS EXPANSION
8.7 NEW PRODUCT LAUNCH
9 COMPANY PROFILES
9.1 ABBOTT LABORATORIES
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGY
9.1.6 SWOT ANALYSIS
9.2 ADVANCED VASCULAR DYNAMICS
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS
9.3 B. BRAUN MELSUNGEN AG
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS
9.4 BIOTRONIK SE & CO. KG
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS
9.5 C.R.BARD INC.
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 KEY DEVELOPMENTS
9.5.5 BUSINESS STRATEGY
9.5.6 SWOT ANALYSIS
9.6 CARDINAL HEALTH INC.
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS STRATEGY
9.6.6 SWOT ANALYSIS
9.7 CARDIVA MEDICALS, INC.
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS STRATEGY
9.7.6 SWOT ANALYSIS
9.8 MORRIS INNOVATIVE, INC.
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS STRATEGY
9.8.6 SWOT ANALYSIS
9.9 SCION BIOMEDICALS, INC.
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGY
9.9.6 SWOT ANALYSIS
9.10 ST.JUDE MEDICAL
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS
9.11 TERUMO CORPORATION
9.11.1 OVERVIEW
9.11.2 FINANCIALS
9.11.3 PRODUCT PORTFOLIO
9.11.4 KEY DEVELOPMENTS
9.11.5 BUSINESS STRATEGY
9.11.6 SWOT ANALYSIS
9.12 VASCULAR SOLUTIONS INC.
9.12.1 OVERVIEW
9.12.2 FINANCIALS
9.12.3 PRODUCT PORTFOLIO
9.12.4 KEY DEVELOPMENTS
9.12.5 BUSINESS STRATEGY
9.12.6 SWOT ANALYSIS
2 INTRODUCTION
2.1 KEY TAKE AWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.5.3 SECONDARY SOURCES
2.5.4 PRIMARY SOURCES
2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing catheterization related procedures
3.3.1.2 Preference for minimally-invasive solutions
3.3.1.3 Ease in usage and quick hemostatic properties of VCDs
3.3.1.4 Increased utilization of transradial arterial access
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 High price of products
3.3.2.2 Complications associated with VCD
3.3.2.3 Less adoption of novel technologies in emerging countries
3.3.2.4 Reduced reimbursement
3.3.2.5 Usage of animal related sources
3.3.2.6 Lower revenue potential of VCD
3.4 PORTER’S FIVE FORCE ANALYSIS
3.4.1 THREAT OF NEW ENTRANTS
3.4.2 THREAT OF SUBSTITUTES
3.4.3 BARGAINING POWER OF SUPPLIERS
3.4.4 BARGAINING POWER OF BUYERS
3.4.5 COMPETITIVE RIVALRY
3.5 REGULATORY AFFAIRS
3.5.1 U.S.
3.5.2 EUROPE
3.5.3 INDIA
3.5.4 CHINA
3.5.5 JAPAN
3.6 REIMBURSEMENT SCENARIO
3.6.1 TRANSCATHETER EMBOLIZATION OR OCCLUSION SERVICES
3.6.2 THROMBOLYSIS
3.6.3 DIAGNOSTIC CARDIAC CATHETERIZATION
3.6.4 INJECTION DIAGNOSTIC CARDIAC CATHETERIZATION
3.7 UPCOMING TECHNOLOGIES
3.8 SUPPLY CHAIN ANALYSIS
3.9 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.10 PATENT TRENDS
4 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY TYPE
4.1 INTRODUCTION
4.2 ACTIVE APPROXIMATORS
4.2.1 CLIPS
4.2.2 SUTURE MEDIATED DEVICES
4.2.3 PLUGS
4.2.3.1 Collagen based
4.2.3.2 Polymer based
4.2.3.3 FISH
4.3 PASSIVE APPROXIMATORS
4.3.1 HEMOSTATIC PADS/PATCHES
4.3.2 COMPRESSION DEVICES
5 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY INTERVENTION
5.1 INTRODUCTION
5.2 DIGNOSTICS
5.3 THERAPEUTICS
6 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY ACCESS
6.1 INTRODUCTION
6.2 FEMORAL ACCESS
6.3 RADIAL ACCESS
7 VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY GEOGRAPHY
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.3 EUROPE
7.4 ASIA PACIFIC
7.5 REST OF THE WORLD
8 COMPANY DEVELOPMENTS
8.1 INTRODUCTION
8.2 ACQUISITION AS A MAJOR GROWTH STRATEGY OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYERS
8.3 MERGERS AND ACQUISITION
8.4 AGREEMENTS PARTERNER SHIPS, COLLABORATIONS & JOINT VENTURES
8.5 APPROVALS
8.6 BUSINESS EXPANSION
8.7 NEW PRODUCT LAUNCH
9 COMPANY PROFILES
9.1 ABBOTT LABORATORIES
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGY
9.1.6 SWOT ANALYSIS
9.2 ADVANCED VASCULAR DYNAMICS
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS
9.3 B. BRAUN MELSUNGEN AG
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS
9.4 BIOTRONIK SE & CO. KG
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS
9.5 C.R.BARD INC.
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 KEY DEVELOPMENTS
9.5.5 BUSINESS STRATEGY
9.5.6 SWOT ANALYSIS
9.6 CARDINAL HEALTH INC.
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS STRATEGY
9.6.6 SWOT ANALYSIS
9.7 CARDIVA MEDICALS, INC.
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS STRATEGY
9.7.6 SWOT ANALYSIS
9.8 MORRIS INNOVATIVE, INC.
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS STRATEGY
9.8.6 SWOT ANALYSIS
9.9 SCION BIOMEDICALS, INC.
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGY
9.9.6 SWOT ANALYSIS
9.10 ST.JUDE MEDICAL
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS
9.11 TERUMO CORPORATION
9.11.1 OVERVIEW
9.11.2 FINANCIALS
9.11.3 PRODUCT PORTFOLIO
9.11.4 KEY DEVELOPMENTS
9.11.5 BUSINESS STRATEGY
9.11.6 SWOT ANALYSIS
9.12 VASCULAR SOLUTIONS INC.
9.12.1 OVERVIEW
9.12.2 FINANCIALS
9.12.3 PRODUCT PORTFOLIO
9.12.4 KEY DEVELOPMENTS
9.12.5 BUSINESS STRATEGY
9.12.6 SWOT ANALYSIS
LIST OF TABLES
Table 1 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 2 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 3 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 4 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 5 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 6 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 7 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, (2015-2022) ($MN)
Table 8 CLIPS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 9 SUTURE MEDIATED DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 10 PLUGS GLOBAL MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 11 PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 12 COLLAGEN BASED PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 13 POLYMER BASED PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 14 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 15 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 16 HEMOSTATIC PADS/PATCHES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 17 COMPRESSION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 18 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 19 DIAGNOSTICS VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 20 THERAPEUTICS VASCULAR CLOSURE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 21 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 22 FEMORAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 23 RADIAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 24 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 25 NORTH AMERICAN ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 26 NORTH AMERICAN PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 27 NORTH AMERICAN PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 28 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 29 NORTH AMERICAN VASCULAR CLOSURE DEVICE MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 30 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 31 EUROPEAN ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 32 EUROPEAN PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 33 EUROPEAN PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 34 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 35 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 36 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 37 ASIA-PACIFIC ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 38 ASIA-PACIFIC PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 39 ASIA-PACIFIC PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODCUT, (2014-2022) ($MN)
Table 40 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 41 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 42 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 43 ROW ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 44 ROW PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 45 ROW PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 46 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 47 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 48 MERGERS AND ACQUISITION (2011-2015)
Table 49 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2012-2015)
Table 50 APPROVALS (2011-2015)
Table 51 BUSINESS EXPANSION (2011-2015)
Table 52 NEW PRODUCT LAUNCH (2011-2015)
Table 53 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 54 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
Table 55 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 56 B.BRAUN MELSUNGEN AG: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 57 B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 58 B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 59 C.R.BARD INC.: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($MN)
Table 60 C.R.BARD INC: TOTAL REVENUE, BY SEGMENT, (2013-15) ($MN)
Table 61 C.R.BARD INC: TOTAL REVENUE, BY REGION, (2013-15) ($MN)
Table 62 CARDINAL HEALTH, INC.: TOTAL REVENUE AND OPERATING EXPENSES, (2013-2015) ($MN)
Table 63 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
Table 64 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 65 ST JUDE MEDICAL: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 66 ST JUDE MEDICAL: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
Table 67 ST.JUDE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 68 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 69 TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 70 TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 71 VASCULAR SOLUTIONS INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 72 VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
Table 73 VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 1 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 2 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 3 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 4 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 5 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 6 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 7 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, (2015-2022) ($MN)
Table 8 CLIPS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 9 SUTURE MEDIATED DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 10 PLUGS GLOBAL MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 11 PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 12 COLLAGEN BASED PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 13 POLYMER BASED PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 14 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 15 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 16 HEMOSTATIC PADS/PATCHES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 17 COMPRESSION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 18 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 19 DIAGNOSTICS VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 20 THERAPEUTICS VASCULAR CLOSURE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 21 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 22 FEMORAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 23 RADIAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
Table 24 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 25 NORTH AMERICAN ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 26 NORTH AMERICAN PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 27 NORTH AMERICAN PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 28 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 29 NORTH AMERICAN VASCULAR CLOSURE DEVICE MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 30 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 31 EUROPEAN ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 32 EUROPEAN PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 33 EUROPEAN PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 34 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 35 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 36 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 37 ASIA-PACIFIC ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 38 ASIA-PACIFIC PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 39 ASIA-PACIFIC PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODCUT, (2014-2022) ($MN)
Table 40 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 41 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 42 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Table 43 ROW ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 44 ROW PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
Table 45 ROW PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
Table 46 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
Table 47 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
Table 48 MERGERS AND ACQUISITION (2011-2015)
Table 49 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2012-2015)
Table 50 APPROVALS (2011-2015)
Table 51 BUSINESS EXPANSION (2011-2015)
Table 52 NEW PRODUCT LAUNCH (2011-2015)
Table 53 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 54 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
Table 55 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 56 B.BRAUN MELSUNGEN AG: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
Table 57 B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
Table 58 B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
Table 59 C.R.BARD INC.: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($MN)
Table 60 C.R.BARD INC: TOTAL REVENUE, BY SEGMENT, (2013-15) ($MN)
Table 61 C.R.BARD INC: TOTAL REVENUE, BY REGION, (2013-15) ($MN)
Table 62 CARDINAL HEALTH, INC.: TOTAL REVENUE AND OPERATING EXPENSES, (2013-2015) ($MN)
Table 63 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
Table 64 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 65 ST JUDE MEDICAL: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 66 ST JUDE MEDICAL: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
Table 67 ST.JUDE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 68 TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 69 TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
Table 70 TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
Table 71 VASCULAR SOLUTIONS INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
Table 72 VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
Table 73 VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
LIST OF FIGURES
Figure 1 VASCULAR CLOSURE DEVICE GLOBAL MARKET SHARE, BY GEOGRAPHY, (2014-22) ($MN)
Figure 2 RESEARCH METHODOLOGY: VASCULAR CLOSURE DEVICES MARKET
Figure 3 VASCULAR CLOSURE DEVICES MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
Figure 4 VASCULAR CLOSURE DEVICES MARKET: FORECASTING MODEL
Figure 5 VASCULAR CLOSURE DEVICES MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION
Figure 6 VASCULAR CLOSURE DEVICES MARKET: MARKET SEGMENTATION
Figure 7 MARKET DYNAMICS
Figure 8 VASCULAR CLOSURE DEVICES MARKET: PORTER’S ANALYSIS
Figure 9 VASCULAR CLOSURE DEVICE MARKET: SUPPLY CHAIN ANALYSIS
Figure 10 VASCULAR CLOSURE DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%)
Figure 11 VASCULAR CLOSURE DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2011-2015)
Figure 12 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Figure 13 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, 2015, ($MN)
Figure 14 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, (2014-2022), ($MN)
Figure 15 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY INTERVENTION, (2014-22) ($MN)
Figure 16 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2015 V’S 2022) ($MN)
Figure 17 RADIAL ACCESS DEVICES GLOBAL MARKET SHARE, BY REGION, 2015, (%)
Figure 18 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) (CAGR %)
Figure 19 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN)
Figure 20 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN)
Figure 21 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN)
Figure 22 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN)
Figure 23 KEY GROWTH STRATEGIES (2012-2015)
Figure 24 SWOT: ABBOTT LABORATORIES
Figure 25 SWOT: ADVANCED VASCULAR DYNAMICS
Figure 26 SWOT: B.BRAUN MELSUNGEN AG
Figure 27 SWOT: BIOTRONIK SE & CO. KG
Figure 28 SWOT: C.R.BARD INC.
Figure 29 SWOT: CARDINAL HEALTH, INC.
Figure 30 SWOT: CARDIVA MEDICALS, INC.
Figure 31 SWOT: MORRIS INNOVATIVE MEDICALS, CORP.
Figure 32 SWOT: SCION BIOMEDICAL, INC.
Figure 33 SWOT: ST.JUDE MEDICAL
Figure 34 SWOT: TERUMO CORPORATION
Figure 35 SWOT: VASCULAR SOLUTIONS INC.
Figure 1 VASCULAR CLOSURE DEVICE GLOBAL MARKET SHARE, BY GEOGRAPHY, (2014-22) ($MN)
Figure 2 RESEARCH METHODOLOGY: VASCULAR CLOSURE DEVICES MARKET
Figure 3 VASCULAR CLOSURE DEVICES MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
Figure 4 VASCULAR CLOSURE DEVICES MARKET: FORECASTING MODEL
Figure 5 VASCULAR CLOSURE DEVICES MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION
Figure 6 VASCULAR CLOSURE DEVICES MARKET: MARKET SEGMENTATION
Figure 7 MARKET DYNAMICS
Figure 8 VASCULAR CLOSURE DEVICES MARKET: PORTER’S ANALYSIS
Figure 9 VASCULAR CLOSURE DEVICE MARKET: SUPPLY CHAIN ANALYSIS
Figure 10 VASCULAR CLOSURE DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%)
Figure 11 VASCULAR CLOSURE DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2011-2015)
Figure 12 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
Figure 13 ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, 2015, ($MN)
Figure 14 PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, (2014-2022), ($MN)
Figure 15 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY INTERVENTION, (2014-22) ($MN)
Figure 16 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2015 V’S 2022) ($MN)
Figure 17 RADIAL ACCESS DEVICES GLOBAL MARKET SHARE, BY REGION, 2015, (%)
Figure 18 VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) (CAGR %)
Figure 19 NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN)
Figure 20 EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN)
Figure 21 ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN)
Figure 22 ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V’S 2022) ($MN)
Figure 23 KEY GROWTH STRATEGIES (2012-2015)
Figure 24 SWOT: ABBOTT LABORATORIES
Figure 25 SWOT: ADVANCED VASCULAR DYNAMICS
Figure 26 SWOT: B.BRAUN MELSUNGEN AG
Figure 27 SWOT: BIOTRONIK SE & CO. KG
Figure 28 SWOT: C.R.BARD INC.
Figure 29 SWOT: CARDINAL HEALTH, INC.
Figure 30 SWOT: CARDIVA MEDICALS, INC.
Figure 31 SWOT: MORRIS INNOVATIVE MEDICALS, CORP.
Figure 32 SWOT: SCION BIOMEDICAL, INC.
Figure 33 SWOT: ST.JUDE MEDICAL
Figure 34 SWOT: TERUMO CORPORATION
Figure 35 SWOT: VASCULAR SOLUTIONS INC.
